Business

US vs China: Goodwin Attorneys Discuss Patent Hurdles and Adalimumab Marketing

February 17th 2021

Huiya Wu, JD, and Freddy Yip, PhD, PCLL, attorneys at Goodwin Procter, discussed biologic drug patent laws in China and the US.

Coherus Files Adalimumab BLA, Although Intended Concentration Is Unclear

February 17th 2021

By Tony Hagen

Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.

Not So Different: Steven Lucio Discusses BI’s Citizen Petition and the Current Status of Biosimilars

February 14th 2021

We sat down with Steven Lucio, PharmD, BCPS, senior principal of Pharmacy Solutions for Vizient, to discuss Boehringer Ingelheim's recent citizen's petition to the FDA.

Steven Lucio Discusses the Changing Dynamics of the Adalimumab Market

February 9th 2021

Steven Lucio, PharmD, BCPS, vice president of Pharmacy Solutions for Vizient, discussed Vizient’s forecast for adalimumab price increases and the market implications of high-concentration adalimumab.

Roche's 2020 Losses to Biosimilars Were "Worst It Can Get"

February 9th 2021

Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.

Study: Biosimilar Use Varies by Type of Institution and Physician Characteristics

February 8th 2021

By Tony Hagen

Physician specialty and practice setting each play a significant role in whether biosimilars are administered vs originators, according to a large, cross-sectional study.

Not So Different: The Race to the Top: Does China Have What It Takes?

February 7th 2021

China’s regulatory reforms and policy enhancements bode well for a thriving biosimilars industry.

Amgen Profits Get a Ride on Biosimilar Growth

February 4th 2021

By Tony Hagen

Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.

Celltrion Executive Discusses Adalimumab Biosimilar Candidate

February 3rd 2021

HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion Healthcare, discusses how the company’s adalimumab biosimilar candidate, CT-P17, stands out from the competition.

Pfizer Biosimilar Revenues Top $525 Million in Fourth Quarter 2020

February 3rd 2021

By Tony Hagen

Pfizer's investment in biosimilars is starting to pay off, as it now ranks these agents among its top revenue drivers.